Forty States Joined Medicaid Drug Pricing Initiative

Healthcare providers and state pharmacy managers should track how this model reshapes drug reimbursement benchmarks.

Updated on Sept. 18, 2026 in Healthcare

Isometric editorial illustration of a large steel shipping crate with a medical cross on a white plinth, representing Medicaid drug policy. — Forty states and Puerto Rico have joined the CMS Generous Model, a new Medicaid initiative aiming to lower therapy costs through international pricing benchmarks. AI Illustration. Upload story photo >

Live Poll

Should federal drug pricing models that limit manufacturer costs be expanded to all states?

Forty states and Puerto Rico have joined the CMS Generous Model, a Medicaid drug payment initiative that launched in January 2026. The program aims to lower taxpayer costs for oncology, diabetes, and asthma therapies by requiring manufacturers to meet international pricing benchmarks.

Why it matters

By shifting drug costs to most-favored-nation pricing, the model seeks to generate significant taxpayer savings and redistribute funds within state Medicaid programs. These changes alter the fiscal landscape for state-level health operations and pharmaceutical procurement.

The five-year initiative is projected to save $5.2 billion annually, with cumulative federal and state savings estimated at $36.6 billion and $27.6 billion respectively over the next decade. All 50 states, the District of Columbia, and Puerto Rico originally applied to participate.

The players

CMS

The federal agency within the Department of Health and Human Services that oversees the Medicare and Medicaid programs, setting standards for healthcare delivery and reimbursement.

Council of Economic Advisers

An agency within the Executive Office of the President that provides economic analysis and long-term federal savings projections for administration policy initiatives.

The details

The Generous Model requires participating pharmaceutical manufacturers to supply covered outpatient drugs to Medicaid programs at most-favored-nation prices. To enforce this, state programs invoice manufacturers for supplemental rebates designed to align costs with international price benchmarks. CMS then reduces the federal share of Medicaid payments to share in these collected rebates, effectively standardizing a lower price floor for expensive therapies.

The five-year model launched in January 2026.
CMS announced 40 states had joined the model on September 18, 2026.
Remaining states have until September 30, 2026, to join the initiative.

Market Landscape

This initiative follows the pattern established by the Inflation Reduction Act's Medicare drug-price negotiation provisions by utilizing federal and state purchasing power to influence pharmaceutical pricing. It represents a broader regulatory trend toward standardizing most-favored-nation pricing across government-funded health programs.

Operators in the pharmaceutical and healthcare supply chain should prepare for potential adjustments to reimbursement rates and supplemental rebate processes. Monitoring state-level participation is critical, as states finalizing their agreements by the September deadline will move quickly to implement these pricing benchmarks.

The takeaway

The CMS Generous Model forces a shift toward international price parity for Medicaid-covered oncology, diabetes, and asthma drugs. Owners should monitor state-specific rebate invoice requirements, as these could impact cash flow and contract terms for entities managing state-level health services.